Cellular Defense: Biotechnology as the Strategic Frontier for NATO
Analyzing the integration of biological sciences and military innovation to enhance troop protection, CBRN defense, and operational resilience within the NATO framework.
6 pages · PDF · 07 January 2026 · Licensed single-user copy, watermarked to the buyer
€299 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
See a sample before you buy. Read the full public summary of this report — free, no account needed: Read the free sample →
Not deciding today? Leave your e-mail and we will send you the free public summary of this report and answer any question before you buy. Optional — the purchase above works without it.
Sold by STRONCATURE S.R.L. (VAT IT05960160652) · Secure checkout by Stripe · Instant watermarked PDF · EU invoice issued after payment.
What this report covers
Technologies: Biotechnology, Human Enhancement & MedTech. A sourced, structured 6-page analysis for European defence and dual-use decision-makers, from the DFM research desk and built on official and primary sources.
About this report
Biotechnology has ceased to be an exclusively civilian domain, transforming instead into a disruptive force within the landscape of global security and collective defense. NATO has officially identified biotechnology and human enhancement technologies as a priority area within the Emerging and Disruptive Technologies (EDTs) essential for maintaining a tactical edge.
The concept of “Cellular Defense” emerges as a necessary response to a threat environment where bioconvergence integrates biology, data, and molecular engineering. Strategic foresight analyses highlight how this technological fusion is rewriting the paradigms of national resilience and the protection of troops on the ground.
Key questions this report answers
- What does NATO's designation of biotechnology and human enhancement as a priority Emerging and Disruptive Technology mean for collective defence?
- How does the concept of Cellular Defense respond to a threat environment shaped by bioconvergence of biology, data, and molecular engineering?
- Why is biotechnology described as no longer an exclusively civilian domain but a disruptive force in global security?
- What readiness and investment gaps must NATO close to translate bioconvergence into national resilience and troop protection?
Who it's for
Strategy, corporate-development and investment teams that need an ecosystem-level view — budgets, industrial capacity and technology landscapes — before committing capital or capacity.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (07 January 2026). You receive a 6-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
More Strategic reports · Biotechnology, Human Enhancement & MedTech · Free summary of this report · All reports
For your role
Investors
Investment intelligence on this company or segment
Request an investment-intelligence brief →SMEs & scale-ups
Position your capability with European programmes
Request a positioning & funding-eligibility check →Universities & research
Technology scouting and multi-seat access for your group
Request technology scouting / team access →Legal & compliance
Eligibility, export-control and regulatory analysis
Request a compliance analysis →Institutional & team access. Labs, primes and universities can equip a whole desk — multi-seat / institutional licensing. Request team / institutional access →
Follow Biotechnology, Human Enhancement & MedTech
Get notified by email when DFM publishes new reports on this topic. Free, unsubscribe anytime.
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →